Profil
Cino Sitia served as the Chief Executive Officer of Postalmarket SpA from 1966 to 1970.
He also worked as a Director at Xeptagen SpA, a Founding Partner at Mida Spa, and a Principal at Cegos Italia SpA. Mr. Sitia earned an undergraduate degree from the University of Genoa in 1957.
Ehemalige bekannte Positionen von Cino Sitia
| Unternehmen | Position | Ende |
|---|---|---|
Postalmarket SpA
Postalmarket SpA Apparel/Footwear RetailRetail Trade Operates chain of retailing outlets | Präsident | 01.01.1970 |
Mida Spa
Mida Spa Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Corporate Officer/Principal | - |
Cegos Italia SpA
Cegos Italia SpA Miscellaneous Commercial ServicesCommercial Services Provides professional training and coaching services | Corporate Officer/Principal | - |
Xeptagen SpA
Xeptagen SpA Medical SpecialtiesHealth Technology Engages in the discovery and validation of molecular biomarkers in order to produce diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy | Direktor/Vorstandsmitglied | - |
Ausbildung von Cino Sitia
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Postalmarket SpA
Postalmarket SpA Apparel/Footwear RetailRetail Trade Operates chain of retailing outlets | Retail Trade |
University of Genoa
University of Genoa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mida Spa
Mida Spa Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Cegos Italia SpA
Cegos Italia SpA Miscellaneous Commercial ServicesCommercial Services Provides professional training and coaching services | Commercial Services |
Xeptagen SpA
Xeptagen SpA Medical SpecialtiesHealth Technology Engages in the discovery and validation of molecular biomarkers in order to produce diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy | Health Technology |
















